Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Nanoparticles for the treatment of osteoporosis

1 Departamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia. Universidad Complutense de Madrid, Instituto de Investigaci ́on Sanitaria Hospital 12 de Octubre i + 12, Plaza de Ramón y Cajal s/n, E-28040 Madrid, Spain
2 Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain

Topical Section: Cell and Tissue Engineering

Osteoporosis is by far the most frequent metabolic disease affecting bone. Current clinical therapeutic treatments are not able to offer long-term solutions. Most of the clinically used anti-osteoporotic drugs are administered systemically, which might lead to side effects in non-skeletal tissues. Therefore, to solve these disadvantages, researchers have turned to nanotechnologies and nanomaterials to create innovative and alternative treatments. One of the innovative approaches to enhance osteoporosis therapy and prevent potential adverse effects is the development of bone-targeting drug delivery technologies. It minimizes the systemic toxicity and also improves the pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the current available bone targeting drug delivery systems, focusing on nanoparticles, proposed for osteoporosis treatment. Bone targeting delivery systems is still in its infancy, thus, challenges are ahead of us, including the stability and the toxicity issues. Newly developed biomaterials and technologies with potential for safer and more effective drug delivery, require multidisciplinary collaboration between scientists from many different areas, such as chemistry, biology, engineering, medicine, etc, in order to facilitate their clinical applications.
  Article Metrics

Keywords nanoparticles; osteoporosis; drug delivery system; anti-osteoporotic drugs; osteoclast; osteoblast; bone-targeting

Citation: P. Mora-Raimundo, M. Manzano, M. Vallet-Regí. Nanoparticles for the treatment of osteoporosis. AIMS Bioengineering, 2017, 4(2): 259-274. doi: 10.3934/bioeng.2017.2.259


  • 1. Kanis JA, Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4: 368–381.
  • 2. Beck GR, Ha SW, Camalier CE, et al. (2012) Bioactive silica-based nanoparticles stimulate bone-forming osteoblasts, suppress bone-resorbing osteoclasts, and enhance bone mineral density in vivo. Nanomed Nanotechnol Biol Med 8: 793–803.
  • 3. Khajuria DK, Razdan R, Mahapatra DR (2011) Drugs for the management of osteoporosis: a review. Rev Bras Reumatol 51: 365–382.
  • 4. Arcos D, Boccaccini AR, Bohner M, et al. (2014) The relevance of biomaterials to the prevention and treatment of osteoporosis. Acta Biomater 10: 1793–1805.
  • 5. Wei D, Jung J, Yang H, et al. (2016) Nanotechnology treatment options for osteoporosis and its corresponding consequences. Curr Osteoporosis Rep 2016: 1–9.
  • 6. Riggs BL, Melton LJ (2015) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17: 505S–511S.
  • 7. Mackey PA, Whitaker MD (2015) Osteoporosis: a therapeutic update. J Nurse Pract 11: 1011–1017.
  • 8. Hernlund E, Svedbom A, Ivergård M, et al. (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the international osteoporosis foundation (IOF) and the european federation of pharmaceutical industry associations (EFPIA). Arch Osteoporosis 8: 1–115.
  • 9. Kanis JA, McCloskey EV, Johansson H, et al. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 24: 23–57.
  • 10. Kim T, Singh RK, Sil M, et al. (2016) Acta biomaterialia inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers. Acta Biomater 29: 352–364.
  • 11. Hodsman AB, Bauer DC, Dempster DW, et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688–703.
  • 12. Weitzmann MN, Ha SW, Vikulina T, et al. (2015) Bioactive silica nanoparticles reverse age-associated bone loss in mice. Nanomed Nanotechnol Biol Med 11: 959–967.
  • 13. Khajuria DK, Disha C, Vasireddi R, et al. (2016) Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Mat Sci Eng C Mater 63: 78–87.
  • 14. Giger EV, Castagner B, Leroux JC (2013) Biomedical applications of bisphosphonates. J Control Release 167: 175–188.
  • 15. Iñiguez ANM, Clarke BL (2015) Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas 82: 245–255.
  • 16. Kanakaris NK, Petsatodis G, Tagil M, et al. (2009) Is there a role for bone morphogenetic proteins in osteoporotic fractures? Injury 40: S21–S26.
  • 17. Lee D, Heo DN, Kim H, et al. (2016) Inhibition of osteoclast differentiation and bone resorption by bisphosphonate- conjugated gold nanoparticles. Sci Rep 6: 27336–27346.
  • 18. Eriksen EF, Díez PA, Boonen S (2014) Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 58: 126–135.
  • 19. Black DM, Schwartz AV, Ensrud KE, et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296: 2927–2938.
  • 20. Dougall WC, Glaccum M, Charrier K, et al. (1999) RANK is essential for osteoclast and lymph node development. Gene Dev 13: 2412–2424.
  • 21. Trejo CG, Lozano D, Manzano M, et al. (2010) The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model. Biomaterials 31: 8564–8573.
  • 22. Barry M, Pearce H, Cross L, et al. (2016). Advances in nanotechnology for the treatment of osteoporosis. Curr Osteoporosis Rep 14: 87–94.
  • 23. Saini D, Fazil M, Ali MM, et al. (2014). Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 7544: 1–14.
  • 24. Ponnapakkam T, Katikaneni R, Sakon J, et al. (2014) Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today 19: 204–208.
  • 25. Narayanan D, Anitha A, Jayakumar R, et al. (2013) In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles. Mol Pharm 10: 4159–4167.
  • 26. Lindsay R, Krege JH, Marin F, et al. (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int 2016: 1–16.
  • 27. Ong KL, Villarraga ML, Lau E, et al. (2010) Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine J 35: 1794–1800.
  • 28. Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471–491.
  • 29. Canalis E (2010) Update in new anabolic therapies for osteoporosis. J Clin Endocr Metab 95: 1496–1504.
  • 30. Tokatlian T, Segura T (2010) siRNA applications in nanomedicine. Wires Nanomed Nanobi 2: 305–315.
  • 31. Guo B, Wu H, Tang T, et al. (2012) A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 18: 307–314.
  • 32. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75–85.
  • 33. Aoki K, Alles N, Soysa N, et al. (2012) Peptide-based delivery to bone. Adv Drug Deliver Rev 64: 1220–1238.
  • 34. Cenni E, Granchi D, Avnet S, et al. (2008) Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 29: 1400–1411.
  • 35. Choi SW, Kim JH (2007) Design of surface-modified poly(d,l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 122: 24–30.
  • 36. Xinluan W, Yuxiao L, Helena NH, et al. (2015) Systemic drug delivery systems for bone tissue regeneration-a mini review. Curr Pharm Design 21: 1575–1583.
  • 37. Yokogawa K, Miya K, Sekido T, et al. (2001) Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142: 1228–1233.
  • 38. Pignatello R (2011) PLGA-alendronate conjugate as a new biomaterial to produce osteotropic drug nanocarriers. Biomaterials Applications for Nanomedicine. InTech.
  • 39. Heller DA, Levi Y, Pelet JM, et al. (2013) Modular "click-in-emulsion" bone-targeted nanogels. Adv Mater 25: 1449–1454.
  • 40. Willson TM, Henke BR, Momtahen TM, et al. (1996) Bone targeted drugs 2 synthesis of estrogens with hydroxyapatite affinity. Bioorg Med Chem Lett 6: 1047–1050.
  • 41. Yarbrough DK, Hagerman E, Eckert R, et al. (2010) Specific binding and mineralization of calcified surfaces by small peptides. Calcified Tissue Int 86: 58–66.
  • 42. Carrow JK, Gaharwar AK (2015) Bioinspired polymeric nanocomposites for regenerative medicine. Macromol Chem Phys 216: 248–264.
  • 43. Lee MS, Su CM, Yeh JC, et al. (2016) Synthesis of composite magnetic nanoparticles Fe3O4 with alendronate for osteoporosis treatment. Int J Nanomed 11: 4583–4594.
  • 44. Kedmi R, Ben-Arie N, Peer D (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31: 6867–6875.
  • 45. Hwang SJ, Lee JS, Ryu TK, et al. (2016) Alendronate-modified hydroxyapatite nanoparticles for bone-specific dual delivery of drug and bone mineral. Macromol Res 24: 623–628.
  • 46. Lu T, Ma Y, Hu H, et al. (2011) Ethinylestradiol liposome preparation and its effects on ovariectomized rats' osteoporosis. Drug Deliv 18: 468–477.
  • 47. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliver Rev 65: 36–48.
  • 48. Kundu SK, Sharma AR, Lee SS, et al. (2014) Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int 2014: 934605–934619.
  • 49. Madni A, Sarfraz M, Rehman M, et al. (2014) Liposomal drug delivery: a versatile platform for challenging clinical applications. Journal Pharm Pharm Sci 17: 401–426.
  • 50. Fang C, Shi B, Pei YY, et al. (2006) In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci 27: 27–36.
  • 51. Zhang J, Li X, Huang L (2014) Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release 190: 440–450.
  • 52. Hughes J, Yadava P, Mesaros R (2010) Liposomal siRNA delivery. Meth Mol Biol 605: 445.
  • 53. Ropert C (1999) Liposomes as a gene delivery system. Braz J Med Biol Res 32: 163–169.
  • 54. Hengst V, Oussoren C, Kissel T, et al. (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331: 224–227.
  • 55. Vert M, Schwach G, Engel R, et al. (1998) Something new in the field of PLA/GA bioresorbable polymers? J Control Release 53: 85–92.
  • 56. Mooney DT, Mazzoni CL, Breuer C, et al. (1996) Stabilized polyglycolic acid fibre based tubes for tissue engineering. Biomaterials 17: 115–124.
  • 57. Jiang T, Yu X, Carbone EJ, et al. (2014) Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications. Int J Pharm 475: 547–557.
  • 58. Fu YC, Fu TF, Wang HJ, et al. (2014) Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation. Acta Biomater 10: 4583–4596.
  • 59. Cong Y, Quan C, Liu M, et al. (2015) Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. J Biomat Sci Polym E 26: 629–643.
  • 60. Yi H, Wu LQ, Bentley WE, et al. (2005) Biofabrication with chitosan. Biomacromolecules 6: 2881–2894.
  • 61. Aktaş Y, Andrieux K, Alonso MJ, et al. (2005) Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 298: 378–383.
  • 62. Schwarz K, Milne D (1972) Growth-promoting effects of Silicon in rats. Nature 239: 333–334.
  • 63. Jugdaohsingh R (2007) Silicon and bone health. J Nutr Health Aging 11: 99–110.
  • 64. Boyce BF, Yao Z, Xing L (2010) Functions of nuclear factor κB in bone. Ann Ny Acad Sci 1192: 367–375.
  • 65. Nanes MS (2003) Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 321: 1–15.
  • 66. Yamaguchi M, Neale WM (2012) The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol Cell Biochem 359: 399–407.
  • 67. Ha SW, Neale WM, Beck GR (2014) Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano 8: 5898–5910.
  • 68. Liu F, Fang F, Yuan H, et al. (2013) Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 28: 2414–2430.
  • 69. Baeza A, Manzano M, Colilla M, et al. (2016) Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution. Biomater Sci 4: 803–813.
  • 70. Vallet RM, Balas F, Arcos D (2007) Mesoporous materials for drug delivery. Angew Chem 46: 7548–7558.
  • 71. Vallet RM, Rámila A, Del Real RP, et al. (2001) A new property of MCM-41: drug delivery system. Chem Mater 13: 308–311.
  • 72. Sun W, Han Y, Li Z, et al. (2016) Bone-targeted mesoporous silica nanocarrier anchored by zoledronate for cancer bone metastasis. Langmuir 32: 9237–9244.
  • 73. Baeza A, Colilla M, Vallet RM (2015) Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. Expert Opin Drug Del 12: 319–37.
  • 74. Paris JL, Torre PDL, Manzano M, et al. (2016) Decidua-derived mesenchymal stem cells as carriers of mesoporous silica nanoparticles. in vitro and in vivo evaluation on mammary tumors. Acta Biomater 33: 275–282.
  • 75. Jordan A, Scholz R, Maier HK, et al. (2006) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neuro-Oncol 78: 7–14.
  • 76. Figuerola A, Di Corato R, Manna L, et al. (2010) From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 62: 126–143.
  • 77. Choi SY, Song MS, Ryu PD, et al. (2015) Gold nanoparticles promote osteogenic differentiation in human adipose-derived mesenchymal stem cells through the Wnt/beta-catenin signaling pathway. Int J Nanomed 10: 4383–4392.
  • 78. Lee NK, Choi YG, Baik JY, et al. (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852–859.
  • 79. Sul OJ, Kim JC, Kyung TW, et al. (2010) Gold nanoparticles inhibited the receptor activator of nuclear factor-κb ligand (RANKL)-induced osteoclast formation by acting as an antioxidant. Biosci Biotech Bioch 74: 2209–2213.
  • 80. Lean JM, Jagger CJ, Kirstein B, et al. (2015) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146: 728–735.
  • 81. Sahana H, Khajuria DK, Razdan R, et al. (2013) Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis. J Biomed Nanotechnol 9: 193–201.
  • 82. Lin L, Chow KL, Leng Y (2009) Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells. J Biomed Mater Res Part A 89: 326–335.
  • 83. Webster TJ, Ergun C, Doremus RH, et al. (2000) Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials 21: 1803–1810.
  • 84. Yamaguchi M (2010) Role of nutritional zinc in the prevention of osteoporosis. Mol Cell Biochem 338: 241–254.
  • 85. Ito A, Otsuka M, Kawamura H, et al. (2005) Zinc-containing tricalcium phosphate and related materials for promoting bone formation. Curr Appl Phys 5: 402–406.


This article has been cited by

  • 1. A.J. Salinas, M. Vallet-Regi, J. Heikkilä, , Bioactive Glasses, 2018, 337, 10.1016/B978-0-08-100936-9.00014-9
  • 2. Parichart Naruphontjirakul, Alexandra E. Porter, Julian R. Jones, In vitro osteogenesis by intracellular uptake of strontium containing bioactive glass nanoparticles, Acta Biomaterialia, 2017, 10.1016/j.actbio.2017.11.008
  • 3. Siming Yu, Kar-Him Luk, Siu-To Cheung, Kevin Wing-Hin Kwok, Ka-Hing Wong, Tianfeng Chen, Polysaccharide-protein complex-decorated selenium nanosystem as an efficient bone-formation therapeutic, Journal of Materials Chemistry B, 2018, 10.1039/C8TB01084F
  • 4. Jay R. Dave, Ankush M. Dewle, Suhas T. Mhaske, Prashant T. Phulpagar, Vikas L. Mathe, Supriya E. More, Ayesha A. Khan, Appala Venkata Ramana Murthy, Suwarna S. Datar, Ajay J. Jog, Megha Page, Geetanjali B. Tomar, Hydroxyapatite nanorods loaded with parathyroid hormone (PTH) synergistically enhance the net formative effect of PTH anabolic therapy, Nanomedicine: Nanotechnology, Biology and Medicine, 2018, 10.1016/j.nano.2018.10.003
  • 5. Patricia Mora-Raimundo, Daniel Lozano, Miguel Manzano, María Vallet-Regí, Nanoparticles to Knockdown Osteoporosis-Related Gene and Promote Osteogenic Marker Expression for Osteoporosis Treatment, ACS Nano, 2019, 10.1021/acsnano.9b00241
  • 6. Miguel Gisbert-Garzarán, Miguel Manzano, María Vallet-Regí, Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis, Pharmaceutics, 2020, 12, 1, 83, 10.3390/pharmaceutics12010083
  • 7. Rafael R. Castillo, Daniel Lozano, María Vallet-Regí, Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules, Pharmaceutics, 2020, 12, 5, 432, 10.3390/pharmaceutics12050432
  • 8. María Vallet‐Regí, Daniel Lozano, Blanca González, Isabel Izquierdo‐Barba, Biomaterials against Bone Infection, Advanced Healthcare Materials, 2020, 2000310, 10.1002/adhm.202000310

Reader Comments

your name: *   your email: *  

Copyright Info: 2017, M. Vallet-Regí, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved